Skip to main
ZTS
ZTS logo

Zoetis (ZTS) Stock Forecast & Price Target

Zoetis (ZTS) Analyst Ratings

Based on 27 analyst ratings
Buy
Strong Buy 37%
Buy 37%
Hold 26%
Sell 0%
Strong Sell 0%

Bulls say

Zoetis is poised for continued growth, with an estimated revenue of $555 million from Apoquel, reflecting a 4% year-over-year increase, and substantial contributions from Librela, projecting a significant 132% growth in dog sales and positively impacting overall market dynamics. The firm benefits from its strong market position, leveraging incremental sales growth strategies for both companion and production animal segments, which could enhance operational revenue growth by 20-30 basis points following portfolio adjustments. Furthermore, the upcoming financial estimates suggest robust operational revenue growth of approximately 9.0% for 1Q24, underscoring an optimistic trajectory that exceeds consensus expectations.

Bears say

Zoetis's financial outlook is negatively impacted by a projected deceleration in operational growth rates and earnings per share (EPS), with estimates for 2025 revised down to approximately 5-6%, below Wall Street consensus of 7.1%. The company faces multiple headwinds, including unfavorable foreign exchange impacts and challenges in revenue growth from its key product, Apoquel, suggesting a downward bias in future estimates. Additionally, increasing competition from generics and macroeconomic uncertainties pose significant risks that could further diminish market share and pricing power, contributing to a cautious long-term outlook for Zoetis's stock performance.

Zoetis (ZTS) has been analyzed by 27 analysts, with a consensus rating of Buy. 37% of analysts recommend a Strong Buy, 37% recommend Buy, 26% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zoetis and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zoetis (ZTS) Forecast

Analysts have given Zoetis (ZTS) a Buy based on their latest research and market trends.

According to 27 analysts, Zoetis (ZTS) has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $167.85, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $167.85, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zoetis (ZTS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.